ONTY - Oncothyreon Inc

[Aoghgmb]

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

[Arrgincey]

Strong move off the $1.50 level, so that downtrend has ended, now watching resistance at $4.50.

It will most likely pull back, still some sellers in there.

[ataocarujr]

booyah...news
UPDATE 2-Merck to test stimuvax cancer drug in Phase III
Mon Jun 22, 2009 2:12pm EDT
* Merck says will test drug against advanced breast cancer
* Company in race to bring cancer vaccine to market

* Oncothyreon shares jump 18 percent (Adds Oncothyreon stock movement)

FRANKFURT, June 22 (Reuters) - Merck KGaA (MRCG.DE) moved its experimental cancer vaccine Stimuvax into the third and last phase of testing required for regulatory approval to investigate its use against breast cancer.

Germany's Merck, which co-develops Stimuvax with U.S. biotech firm Oncothyreon (ONTY.O) (ONY.TO), said on Monday the trial, dubbed STRIDE(a), will involve patients with advanced, inoperable breast cancer.
The news sent the shares of Oncothyreon up 17.8 percent to C$3.04 on the Toronto Stock Exchange on Monday afternoon after touching a high of C$3.20 earlier in the day. On Nasdaq, the shares were up 16.7 percent at $2.66.

The small biotechnology company changed its name from Biomira and moved to the United States from Canada late last year.

Breast cancer is the second most common form of cancer after lung cancer and is the leading cause of cancer deaths in women.

The drug, which is also being tested against lung cancer in Phase III, has been shown to prime the body's immune system to detect and attack cancer cells.

Germany's Merck is racing with biotech firms including Transgene (TRNG.PA), Dendreon Corp (DNDN.O) and Antigenics (AGEN.O) to bring cancer vaccines to market.

While Transgene's TG4010 compound also targets lung tumors, the most common form of cancer, the Dendreon and Antigenics drug candidates are aimed at prostate cancer and brain cancer, respectively. (Reporting by Ludwig Burger and Scott Anderson in Toronto; editing by Peter Galloway)

[bayaduf]

dilution monster strikes again...

Oncothyreon Selling $14.9M In Equity; Shares Slide
Friday 09/24/2010 9:28 AM ET - Dow Jones News


DOW JONES NEWSWIRES
Oncothyreon Inc. (ONTY) is selling $14.9 million of stock through a private placement, becoming the latest drug developer recently to raise capital through an equity sale.
Shares of the cancer drug maker dropped 13.1% to $3.65 in recent premarket trading, adding to a 2010 drop of 22% through Thursday.
The latest deal follows an announcement in July that an investor, Small Cap Biotech Value Ltd., committed to buying $20 million of equity over the next two years. That came as Oncothyreon and German drug maker Merck KGaA (MKGAY, MRK.XE) resumed development of an experimental lung cancer vaccine after the Food and Drug Administration partially lifted a clinical hold on the treatment.
Under Friday's announcement, Oncotyhreon is selling 4.2 million units--consisting of one share and a warrant to buy 0.75 share--for $3.50 each. Oncothyreon had about 26 million shares outstanding as of June 30.

[admin]

Update on the earnings announcement. They released a statement saying that their earnings will be announced via a conference call on 3/14/2013 at 0830 am.
http://finance.yahoo.com/news/oncothyreon-announces-full-fourth-quarter-130000250.html